US bill aims to tackle rise in false patent marking suits
This article was originally published in Clinica
A new bill introduced in the US House of Representatives aims to restrict the penalties that are being awarded to plaintiffs that have sued companies for alleged false patent markings. The Patent Lawsuit Reform Act of 2010, if signed into law, would bring relief to companies across all sectors – including pharmaceutical and medtech entities – that have been flooded with such lawsuits in the recent past.
You may also be interested in...
The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-eight guidance documents have been posted on the tracker since its last update.